1st Circ. Presses Ex-Aveo CFO On Candor With Analyst

Law360 (October 6, 2020, 3:48 PM EDT) -- Aveo Pharmaceuticals' former finance chief struggled to convince a First Circuit panel Tuesday that he was truthful when he told a stock analyst the U.S. Food and Drug Administration hadn't brought up needing further trials for a kidney cancer drug, with the panel pointing out the agency had said as much at a meeting months prior.

The three-judge panel skeptically weighed the argument from David Johnston, Aveo's former chief financial officer, who is seeking to toss a Boston federal jury's November 2018 verdict finding him liable in the U.S. Securities and Exchange Commission suit, as well as a two-year restriction on...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!